Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 4/20 | 0.36 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.34 |
| ▸ | ULK1 | O75385 | 1/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495162 | 0.91 | PTK2 (0.36) | SLC2A1SYKPKMYT1SLC9A1PRKCQ | |
| SCHEMBL3497196 | 0.88 | PRKCQ (0.47) | SYKSLC9A1PRKCQLRRK2PTK2 | |
| SCHEMBL3496014 | 0.88 | LRRK2 (0.40) | SLC2A1SYKPKMYT1PRKCQLRRK2 | |
| SCHEMBL3495251 | 0.87 | PRKCQ (0.37) | SLC2A1SYKPKMYT1PRKCQLRRK2 | |
| SCHEMBL3495540 | 0.85 | PRKCQ (0.37) | SLC2A1SYKPKMYT1PRKCQLRRK2 | |
| SCHEMBL3494607 | 0.80 | SYK (0.36) | SYKPRKCQLRRK2PTK2ULK1 | |
| SCHEMBL3496445 | 0.80 | ULK1 (0.51) | SYKPRKCQLRRK2ULK1 | |
| SCHEMBL3497097 | 0.79 | PRKCQ (0.37) | SLC2A1SYKPKMYT1PRKCQLRRK2 | |
| SCHEMBL3495604 | 0.79 | SYK (0.36) | SYKPRKCQLRRK2PTK2ULK1 | |
| SCHEMBL3496087 | 0.79 | SYK (0.41) | SLC2A1SYKPKMYT1PRKCQLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | SLC2A1 4131/4885SYK 460/4885PKMYT1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.